UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000045572 |
|---|---|
| Receipt number | R000052024 |
| Scientific Title | Efficacy and safety of hypoglycemic agents in nonalcoholic fatty liver disease with type 2 diabetes |
| Date of disclosure of the study information | 2021/09/27 |
| Last modified on | 2021/09/27 02:04:25 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy and safety of hypoglycemic agents in nonalcoholic fatty liver disease with type 2 diabetes
Acronym
Efficacy and safety of hypoglycemic agents in nonalcoholic fatty liver disease with type 2 diabetes
Scientific Title
Efficacy and safety of hypoglycemic agents in nonalcoholic fatty liver disease with type 2 diabetes
Scientific Title:Acronym
Efficacy and safety of hypoglycemic agents in nonalcoholic fatty liver disease with type 2 diabetes
Region
| Japan |
Condition
Condition
nonalcoholic fatty liver disease with type 2 diabetes
Classification by specialty
| Hepato-biliary-pancreatic medicine |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this study is to investigate the efficacy and safety of various hypoglycemic agents in NAFLD patients with type 2 diabetes.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Changes in liver stiffness 1 year after administration from baseline
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1)age =>20 years
2)Type 2 diabetes
3)Patients with NAFLD diagnosed by clinical data
4)Patients provided with informed consent
Key exclusion criteria
1) daily alcohol consumption =>30 g for males and =>20 g for females
2) other chronic liver diseases, such as viral hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis, Wilson disease, and hemochromatosis
3) pregnancy and lactation
4) Others judged unsuitable by researchers
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | Taeang |
| Middle name | |
| Last name | Arai |
Organization
Nippon Medical School
Division name
Division of Gastroenterology and Hepatology
Zip code
113-8603
Address
1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan.
TEL
03-3822-2131
taeangpark@yahoo.co.jp
Public contact
Name of contact person
| 1st name | Taeang |
| Middle name | |
| Last name | Arai |
Organization
Nippon Medical School
Division name
Division of Gastroenterology and Hepatology
Zip code
113-8603
Address
1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan.
TEL
03-3822-2131
Homepage URL
taeangpark@yahoo.co.jp
Sponsor or person
Institute
Nippon Medical School
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Nippon Medical School Hospital Ethics Committee
Address
1-1-5,Sendagi,Bunkyo-ku,Tokyo,Japan.
Tel
03-3822-2131
nms_fuzokurinri@nms.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 09 | Month | 27 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2021 | Year | 07 | Month | 12 | Day |
Date of IRB
| 2021 | Year | 07 | Month | 12 | Day |
Anticipated trial start date
| 2021 | Year | 09 | Month | 27 | Day |
Last follow-up date
| 2026 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Proactively observe the efficacy and safety of various hypoglycemic agents in patients with NAFLD with type 2 diabetes
Management information
Registered date
| 2021 | Year | 09 | Month | 27 | Day |
Last modified on
| 2021 | Year | 09 | Month | 27 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052024
